DOYLESTOWN, PA. - May 3, 2004 - The Quigley Corporation (Nasdaq: QGLY)
reported today that Terrence O. Tormey has been appointed to the Board of Directors.
Mr. Tormey, age 49, is the President and founder of TOTormey, Inc., a sales and
marketing consulting firm whose services include film and video productions for a
variety of industries, including the healthcare industry. During the years 2000 to 2003,
Mr. Tormey was the President and Chief Operating Officer of Nelson Professional Sales,
a division of Publicis SA, Paris. From 1994 to 2000, Mr. Tormey was the President and
co-owner of The Medical Phone Company®, a firm that eventually grew to the largest
healthcare telesales company in the country, and whose clients included virtually every
major pharmaceutical company in the United States. Additionally, his experience
includes holding various senior sales, sales training, and sales management positions with
various pharmaceutical companies, including Johnson & Johnson and American Home
Products. Mr. Tormey also serves on the Board of Directors of Global Pharmaceutical
Resources, a worldwide consortium of Contract Sales Organizations.
Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "We are excited
to have Terrence join our board. He brings significant operational and sales experience,
including setting up contract sales organizations, as well as a strong pharmaceutical
background. He also has extensive industry contacts and we look forward to his ongoing
contributions and the independent voice Terrence will add to our board."
The Quigley Corporation (Nasdaq: QGLY), www.Quigleyco.com., is a leading developer and
marketer of diversified health products including the Cold-Eeze® family of patented zinc
gluconate glycine (ZIGGTM) lozenges and sugar free tablets. Cold-Eeze is the only (ZIGG™)
lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6
to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the company has
formed Quigley Pharma Inc. www.QuigleyPharma.com, a wholly owned ethical pharmaceutical
subsidiary, to introduce a line of naturally derived patented prescription drugs. The Quigley
Corporation's customers include leading national wholesalers and distributors, as well as
independent and chain food, drug and mass merchandise stores and pharmacies.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or
any other regulatory agency will grant an IND or take any other action to allow the
aforementioned products to be studied or marketed. Furthermore, no claim is made that the
potential medicine discussed here is safe, effective, or approved by the Food and Drug
Administration. Additionally, data that demonstrates activity or effectiveness in animals or in
vitro tests do not necessarily mean that the formula test compound, referenced herein will be
effective in humans. Safety and effectiveness in humans will have to be demonstrated by means
of adequate and well-controlled clinical studies before the clinical significance of the formula test
compound is known.
Certain statements in this press release are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk,
uncertainties and other factors that may cause the company's actual performance or achievements
to be materially different from the results, performance or achievements expressed or implied by
the forward-looking statement. Factors that impact such forward-looking statements include,
among others, changes in worldwide general economic conditions, changes in interest rates,
government regulations, and worldwide competition.
